Treace Q3 revenue $40.8M (+23% YoY); FY2023 guidance cut to $182-186M from $191-197M

TREACE MEDICAL CONCEPTS, INC.

2023-Q3 EPS reported -$0.71 revenue$124,906,000

Q3 revenue $40.8M (+23% YoY) driven by higher kit volume and record ASP of $6,311.
Net loss widened to $17.5M ($0.28/sh) from $12.1M ($0.22/sh) in Q3 2022.
Adjusted EBITDA loss of $9.2M vs $8.6M loss a year ago; expects positive adj. EBITDA in Q4.
Full-year 2023 revenue guidance lowered to $182-186M (28-31% growth) from $191-197M.
Surgeon base grew 21% to 2,691; new technologies launched including Gen 2 SpeedPlate.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TREACE MEDICAL CONCEPTS, INC. reported third quarter ended September 30, 2023 results: revenue $40.8 million, net income ($17.5) million, or ($0.28) per share, EPS ($0.28) per share. Guidance lowered.

Period: third quarter ended September 30, 2023
Revenue: $40.8 million
Net income: ($17.5) million, or ($0.28) per share
EPS: ($0.28) per share
Guidance: lowered
Result: reported results

Exact text from the filing

through its Lapiplasty ® 3D Bunion Correction ® Procedure, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights: • Revenue of $40.8 million in the third quarter, a 23% increase over same period last year and a 36% increase year to date over prior year • Blended average revenue per Lapiplasty ® procedure kit sold was

View on SEC.gov

Browse all earnings releases →

TREACE MEDICAL CONCEPTS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-062026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.